Literature DB >> 17598840

Nephrotic syndrome in a patient with IgM myeloma with associated neutrophilia.

Paola Gnerre1, Luciano Ottonello, Fabrizio Montecucco, Michela Boero, Franco Dallegri.   

Abstract

An unusual case having IgM monoclonal gammopathy with clinical and pathologic features of multiple myeloma (MM) in association with neutrophilia and nephrotic syndrome is reported. The patient showed lytic bone lesions, decreased IgG and IgA levels, Bence-Jones proteinuria, nephrotic proteinuria with edema, and histological plasma cell infiltration typical of MM. Moreover, mature neutrophilic leukocytosis, hepatomegaly, high leukocyte alkaline phosphatase score (LAP), absence of Philadelphia (Ph) chromosome and bcr gene rearrangement were also evidenced, all these features representing findings typical of the recently described plasma cell dyscrasia-associated neutrophilia. After the diagnosis, the patient was treated with melphalan and prednisone, with an excellent response to the treatment. Different from the 30 cases so far reported, this is the first case of plasma-cell dyscrasia with associated neutrophilia due to IgM-producing monoclonal gammopathy. At the same time, this is the first reported case of nephrotic syndrome secondary to IgM myeloma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17598840     DOI: 10.1111/j.1600-0609.2007.00869.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  2 in total

1.  Elevated granulocyte colony-stimulating factor, non-infectious leukocytosis and fevers in a patient with multiple myeloma.

Authors:  Meghan M Sebasky; Pankaj Gupta; Gregory A Filice
Journal:  J Gen Intern Med       Date:  2008-09-23       Impact factor: 5.128

2.  Aseptic abscess in the abdominal wall accompanied by monoclonal gammopathy simulating the local recurrence of rectal cancer: A case report.

Authors:  Yan Yu; Yong-Dong Feng; Chao Zhang; Ran Li; De-An Tian; Huan-Jun Huang
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.